Compare ADBT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADBT | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 37.3M |
| IPO Year | 2025 | 2022 |
| Metric | ADBT | CCEL |
|---|---|---|
| Price | $0.08 | $4.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 9.0K |
| Earning Date | 11-20-2026 | 10-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.01 | ★ 0.23 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $10.89 | $18.04 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.07 | $2.72 |
| 52 Week High | $4.99 | $5.45 |
| Indicator | ADBT | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 6.62 | 42.81 |
| Support Level | N/A | $3.14 |
| Resistance Level | $0.13 | $4.76 |
| Average True Range (ATR) | 0.01 | 0.39 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 19.53 | 8.46 |
Advasa Holdings Inc is a financial technology and services company that offers a suite of financial services and solutions. Its earned wage access (EWA) service, named 'FUKUPE', provides employees with real-time access to their earned wages through cashless receipts and settlements that integrate seamlessly with wallets, cards, and bank accounts. The company also licenses its EWA technology portfolio and offers OEM (original equipment manufacturer) services. The company generates the majority of revenue from the provision of software maintenance services. Geographically, the company operates only in Japan.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.